Welcome to our dedicated page for Vanda Pharmaceuticals SEC filings (Ticker: VNDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Vanda Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Vanda Pharmaceuticals's regulatory disclosures and financial reporting.
Vanda Pharmaceuticals Inc. (VNDA) is reported to have a significant shareholder group consisting of Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. These reporting persons collectively report beneficial ownership of 3,376,401 shares of Vanda common stock, representing 5.6% of the outstanding class.
They report shared voting and shared dispositive power over all 3,376,401 shares, and no sole voting or dispositive power. The shares are held by entities over which Millennium Management LLC and related managers have voting control and investment discretion, and the reporting persons state that this should not, by itself, be construed as an admission of beneficial ownership.
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC report a passive ownership stake in Vanda Pharmaceuticals Inc. common stock. They disclose beneficial ownership of 3,497,695 shares, representing 5.82% of Vanda’s outstanding common stock as of the filing date.
Both entities report no sole voting or dispositive power. They have shared voting power over 3,313,298 shares and shared dispositive power over all 3,497,695 shares. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC, and the Schedule is filed on behalf of both.
Vanda Pharmaceuticals reported Q2 2026 total revenues of $50.5 million, down 4% year-over-year, as Fanapt net product sales grew 23% to $36.0 million while HETLIOZ declined 66% to $5.6 million. Net loss widened to $62.5 million (diluted loss per share $1.04) as R&D and SG&A spending increased.
Cash, cash equivalents and marketable securities totaled $170.0 million at June 30, 2026, and the company expects its resources and anticipated revenues to fund operations through at least the end of 2027. Management reiterated 2026 total revenue guidance of $240 to $290 million and highlighted FDA approval of milsaperidone for bipolar I disorder and schizophrenia, NEREUS commercial launch, an imsidolimab BLA with a December 12, 2026 PDUFA date, multiple Phase III readouts through early 2027, and ongoing proceedings to seek HETLIOZ approval for jet lag disorder.
McGuire Daniel Patrick reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals reported that SVP, General Counsel and Secretary Daniel Patrick McGuire received a grant of 80,000 shares of common stock underlying a restricted stock unit (RSU) award at no cash cost per share. His direct ownership after the grant is 109,982 common shares.
The RSU award vests in four equal annual installments beginning on June 4, 2027, as long as he remains continuously employed through each vesting date. Vested shares will be delivered on the first permissible trading day on or after each vesting date, making this a routine equity-based compensation grant rather than an open-market trade.
Chrousos Phaedra reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals director Phaedra Chrousos received a grant of 41,600 shares of Common Stock in the form of time-based restricted stock units. The award was granted at no cash cost per share and is part of her equity compensation.
All 41,600 RSU shares will vest on June 4, 2027, provided she continues to serve the company through that date. Following this grant, she directly holds 164,950 shares of Vanda Pharmaceuticals common stock.
Duncan Charles Cliff reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals director Charles Cliff received a grant of 41,600 shares of common stock in the form of time-based restricted stock units at no purchase price. These RSUs vest in full on June 4, 2027 if he remains in continuous service, bringing his direct holdings to 98,701 shares.
DUGAN RICHARD W reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals Inc. director Richard W. Dugan reported an equity compensation grant in the form of restricted stock units. On June 4, 2026, he was awarded 41,600 shares of common stock underlying a time-based RSU that vests 100% on June 4, 2027, contingent on continuous service. Following this grant, Dugan holds 219,054 shares of Vanda common stock directly.
Ward Anne Sempowski reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals Inc. director Anne Sempowski Ward received an equity award covering 41,600 shares of common stock in the form of time-based restricted stock units. The award was granted at no cash cost to her and is scheduled to vest in full on June 4, 2027, if she continues serving the company through that date. After this grant, she is reported as beneficially owning 160,667 shares of Vanda common stock directly.
Vanda Pharmaceuticals director Honore Tage received a grant of 41,600 shares of common stock through a restricted stock unit (RSU) award. The RSUs are time-based and will vest 100% on June 4, 2027, if Tage continues to provide service to the company through that date.
Following this grant, Tage directly holds 135,069 shares of Vanda Pharmaceuticals common stock. Because the shares were awarded as equity compensation at no cash cost, this filing reflects a compensation-related acquisition rather than an open-market purchase.